Summit Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 0.00 shares.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 0.00 shares.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-03-31 was 177.24K shares, a 1377.59% increase year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-12-31 was 49.96K shares, a 87.85% decline year-over-year.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 61.95K shares, a 94.49% decline from fiscal 2021.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 1.12M shares, a 256.55% increase from fiscal 2020.
- Summit Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 315.41K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 227.20K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 227.20K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 177.24K shares 10-Q · filed 2023-05-11 | 227.20K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 49.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 61.95K shares 10-K · filed 2023-03-09 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 423.02K shares derived: sum of 4 quarters · filed 2022-12-21 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 699.74K shares derived: sum of 4 quarters · filed 2022-12-21 |
| 2022-03-31 | 11.99K shares 10-Q · filed 2022-05-11 | 819.04K shares derived: sum of 4 quarters · filed 2022-12-21 |
| 2021-12-31 | 411.03K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | 1.12M shares 10-K/A · filed 2022-12-21 |
| 2021-09-30 | 276.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2021-06-30 | 119.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 317.54K shares 10-Q · filed 2021-05-17 | |
| 2020-12-31 | 315.41K shares 10-K · filed 2021-03-31 | |
| 2019-01-31 | 0.00 shares 8-K · filed 2020-09-29 | |
| 2018-01-31 | 0.00 shares 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |